Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Isofol Medical AB ( (SE:ISOFOL) ) has issued an update.
Isofol Medical AB announced a webcast presentation and Q&A session for its second-quarter 2025 interim report, scheduled for August 26. The session, led by CEO Petter Segelman Lindqvist and CFO Margareta Hagman, will cover the company’s recent progress and financial status, providing stakeholders with insights into its ongoing operations and strategic direction.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company’s primary product is arfolitixorin, a drug candidate designed to enhance the effectiveness of first-line standard treatments for various solid tumors, with a current focus on colorectal cancer. Isofol Medical AB is publicly traded on Nasdaq Stockholm.
Average Trading Volume: 1,405,882
Technical Sentiment Signal: Sell
Current Market Cap: SEK242.3M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.